← Human Trials & Peer-Reviewed Studies
The effect of intravenous corticotropin-releasing hormone administration on esophageal sensitivity and motility in health
Plain-language guide to PMID 28336550 (2017): placebo-controlled clinical trial study of ACTH (Corticotropin) and CRH (Corticotropin-Releasing Hormone) in 14 subjects.
Key Facts
- PMID
- 28336550
- Journal
- American journal of physiology. Gastrointestinal and liver physiology
- Year
- 2017
- Study type
- Clinical Trial
- Authors
- Broers C et al. (9 authors)
- DOI
- 10.1152/ajpgi.00437.2016
What This Study Did, in Plain Language
What Was Tested
Researchers studied ACTH (Corticotropin) and CRH (Corticotropin-Releasing Hormone) in this clinical trial publication.
Esophageal hypersensitivity is important in gastroesophageal reflux disease (GERD) patients who are refractory to acid-suppressive therapy.
Stress affects visceral sensitivity and exacerbates heartburn in GERD.
Who Took Part
The abstract describes 14 subjects taking part.
By PubMed's age tags, the people studied were teenagers, young adults, adults and middle-aged adults, both men and women.
How the Study Was Run
The researchers set it up as a placebo-controlled study.
Some subjects received a placebo instead of ACTH (Corticotropin), giving a reference point.
Perception scores were assessed for first perception, pain perception threshold (PPT), and pain tolerance threshold (PTT).
Stress and mood were assessed during the study.
What Was Measured
Esophageal motility was investigated by high-resolution impedance manometry, before and after CRH and evaluated by distal contractile integral (DCI) and intrabolus pressure (IBP).
Pressure flow analysis assessed bolus clearance (impedance ratio), degree of pressurization needed to propel bolus onward (IBP slope), and pressure flow (pressure flow index, PFI).
PubMed files the paper under topics including Corticotropin-Releasing Hormone, Deglutition, Esophagus, Gastrointestinal Motility, Peristalsis and Pressure.
Author keywords: esophageal motility, esophageal sensitivity, gastroesophageal reflux disease and stress.
What This Means in Plain Language
The paper is a placebo-controlled study of ACTH (Corticotropin) and CRH (Corticotropin-Releasing Hormone) in 14 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2017 (American journal of physiology. Gastrointestinal and liver physiology), a journal based in United States.
More context: the ACTH (Corticotropin) compound page and the CRH (Corticotropin-Releasing Hormone) compound page, all human trials.
Our Notes on the Compounds
ACTH (Corticotropin): The 39-amino-acid pituitary hormone that drives cortisol production; given as repository corticotropin (Acthar Gel).
CRH (Corticotropin-Releasing Hormone): The 41-amino-acid hypothalamic hormone that triggers ACTH release; corticorelin is used diagnostically.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.